🔴 Krystal Biotech is trading 22.21% down in after-hours trading with no clear company-specific catalyst identified

Krystal Biotech is trading 22.21% down at $269.59 after no clear company-specific announcement was identified for August 21, 2026.

• Latest reported earnings, released August 3, showed $119.2 million in VYJUVEK revenue and $1.79 diluted EPS; revenue missed expectations, and the report predates this after-hours move.
• The broader market was positive, so macro sentiment does not clearly explain the decline; re-checking for delayed filings or news is warranted.